KaydedilenlerDerginizi ekleyin

Dergiler / İstanbul Kuzey Klinikleri / 2020 / Cilt: 7 - Sayı: 3

Factors affecting survival in esophageal squamous cell carcinoma: Single-center experience

Abdullah SAKİN
Serdar ARICI
Nurgül YAŞAR
Çağlayan GEREDELİ
Şener CİHAN
Süleyman ŞAHİN
Cumhur DEMİR
Yonca YILMAZ ÜRÜN
Muhammed Mustafa ATCI
Sayfa
267–274
Yayın Tarihi
2022-10-18
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

In the metastatic stage, mOS was 8.0 months for thepatients treated with a first-line CT and 3.0 months for patients receiving best supportive care (p

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:OBJECTIVE: Squamous cell esophageal cancer (ESCC) is a highly fatal malignancy.
📊
Temel Bulgular & Veri:This study aims to investigate the factorsaffecting survival in patients with metastatic and non-metastatic ESCC.METHODS: Between 2008 and 2016, 107 patients with ESCC who were followed up in an oncology clinic were included inthe analysis.
💡
Sonuç & Katkı:In the metastatic stage, mOS was 8.0 months for thepatients treated with a first-line CT and 3.0 months for patients receiving best supportive care (p
🔬Tür:Araştırma Makalesi
📍Kapsam:2008 Verileri
⚙️Değişkenler:Alan Parametreleri

Abstract

OBJECTIVE: Squamous cell esophageal cancer (ESCC) is a highly fatal malignancy. This study aims to investigate the factorsaffecting survival in patients with metastatic and non-metastatic ESCC.METHODS: Between 2008 and 2016, 107 patients with ESCC who were followed up in an oncology clinic were included inthe analysis. Patients were grouped based on the stage of disease as clinical-stage II to IV.RESULTS: Of the 107 patients, 55 (55.1%) of them were male and 52 (48.6%) of them were female. The mean age was60.8 years. Based on the clinical-stage, 28 (26.2%) patients had stage II disease, 33 (30.8%) had stage III disease, and 46(43.0%) had stage IV disease. Twenty-nine (27.1%) patients with the non-metastatic disease underwent surgery followingneoadjuvant chemoradiotherapy (CRT), while 29 (27.1%) patients received definitive CRT. Twenty-six (56.5%) patients withmetastatic disease received chemotherapy (CT). While median overall survival (mOS) could not be reached in patients whounderwent surgery following neoadjuvant CRT, mOS for patients receiving definitive CRT versus patients treated with surgeryalone–was 22.0 months and 24.0 months, respectively (p=0.008). In the metastatic stage, mOS was 8.0 months for thepatients treated with a first-line CT and 3.0 months for patients receiving best supportive care (p

🔖

Bu Makaleye Atıf Yap

SAKİN, A., ARICI, S., YAŞAR, N., GEREDELİ, Ç., CİHAN, Ş., ŞAHİN, S., DEMİR, C., ÜRÜN, Y. Y., ATCI, M. M. (2022). Factors affecting survival in esophageal squamous cell carcinoma: Single-center experience. İstanbul Kuzey Klinikleri, Cilt: 7 - Sayı: 3, 267–274. https://ajindex.com/articles/551440

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (12)

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019;69:7–34
  2. Thrift AP. The epidemic of oesophageal carcinoma: Where are we now? Cancer Epidemiol 2016;41:88–95
  3. Pohl H, Sirovich B, Welch HG. Esophageal adenocarcinoma incidence: are we reaching the peak? Cancer Epidemiol Biomarkers Prev 2010;19:1468–70
  4. Baquet CR, Commiskey P, Mack K, Meltzer S, Mishra SI. Esophageal cancer epidemiology in blacks and whites: racial and gender disparities in incidence, mortality, survival rates and histology. J Natl Med Assoc 2005;97:1471–8
  5. Engel LS, Chow WH, Vaughan TL, Gammon MD, Risch HA, Stanford JL, et al. Population attributable risks of esophageal and gastric cancers. J Natl Cancer Inst 2003;95:1404–13
  6. Dandara C, Robertson B, Dzobo K, Moodley L, Parker MI. Patient and tumour characteristics as prognostic markers for oesophageal cancer: a retrospective analysis of a cohort of patients at Groote Schuur Hospital. Eur J Cardiothorac Surg 2016;49:629–34
  7. He Z, Zhao Y, Guo C, Liu Y, Sun M, Liu F, et al. Prevalence and risk factors for esophageal squamous cell cancer and precursor lesions in Anyang, China: a population-based endoscopic survey. Br J Cancer 2010;103:1085–8
  8. Randi G, Scotti L, Bosetti C, Talamini R, Negri E, Levi F, et al. Pipe smoking and cancers of the upper digestive tract. Int J Cancer 2007;121:2049–51. 9. van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, et al; CROSS Group. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012;366:2074–84
  9. Suntharalingam M, Moughan J, Coia LR, Krasna MJ, Kachnic L, Haller DG, et al; 1996-1999 Patterns of Care Study. The national practice for patients receiving radiation therapy for carcinoma of the esophagus: results of the 1996-1999 Patterns of Care Study. Int J Radiat Oncol Biol Phys 2003;56:981–7
  10. Tsuchiya Y, Onda M, Miyashita M, Sasajima K. Serum level of cytokeratin 19 fragment (CYFRA 21-1) indicates tumour stage and prognosis of squamous cell carcinoma of the oesophagus. Med Oncol 1999;16:31–7
  11. Nabeya Y, Shimada H, Okazumi S, Matsubara H, Gunji Y, Suzuki T, et al. Serum cross-linked carboxyterminal telopeptide of type I collagen (ICTP) as a prognostic tumor marker in patients with esophageal squamous cell carcinoma. Cancer 2002;94:940–9
  12. Duan H, Zhang X, Wang FX, Cai MY, Ma GW, Yang H, et al. Prognostic role of neutrophil-lymphocyte ratio in operable esophageal squamous cel